loading page

Improved protection at term with an alternative strategy of prophylactic anti-D administration in pregnancy - a prospective interventional study
  • +4
  • Agneta Wikman,
  • Anette Mörtberg,
  • Elisabeth Jalkesten,
  • Yvonne Jansson,
  • Anita Karlsson,
  • Eleonor Tiblad,
  • Gunilla Ajne
Agneta Wikman
Karolinska Universitetssjukhuset
Author Profile
Anette Mörtberg
Karolinska Universitetssjukhuset
Author Profile
Elisabeth Jalkesten
Karolinska Universitetssjukhuset
Author Profile
Yvonne Jansson
Karolinska Universitetssjukhuset
Author Profile
Anita Karlsson
Karolinska Universitetssjukhuset
Author Profile
Eleonor Tiblad
Karolinska Universitetssjukhuset
Author Profile
Gunilla Ajne
Karolinska Institute
Author Profile

Abstract

Objective: To analyse the proportion of RhD negative women where routine antenatal anti-D prophylaxis (RAADP) in gestational week (gw) 28 is not detectable at delivery and to investigate if a strategy with RAADP administered in gw 28 and 38 result in efficient protection at term, postterm and postdelivery. Design: A retrospective database analysis and a prospective interventional study. Setting: Antenatal centers in the Stockholm region. Sample: RhD negative women carrying an RHD positive fetus, 4280 cases evaluated retrospectively, 39 cases included prospectively. Methods: In a retrospective analysis, RhD negative women with a negative antibody screen at delivery was determined. In 39 pregnancies, quantification of anti-D was analysed before a second dose anti-D was administered in gw 38, and then weekly up to 43 weeks post gestation. Main outcome measures: The proportion of women with non-detectable anti-D at term. The concentration of anti-D measured weekly at term, postterm and postdelivery. Results: In 20,5% (856/4280, retrospective analysis) and 44% (17/39, prospective study) RAADP in gw 28 was below screening detection level, 10 IU/L at term and in 18% (7/39, prospective study) below 1 IU/L in the quantification assay. Anti-D prophylaxis administered in gw 38 showed stable protective levels of anti-D up to 30 days postdelivery, with concentration at delivery 60+34 IU/L (mean+SD). Conclusion: At least one third of the RhD negative women have non-detectable levels of RAADP given at gw 28, at term and postterm. A second dose of RAADP at gw 38 improves the protection.

Peer review status:UNDER REVIEW

14 Jul 2020Submitted to BJOG: An International Journal of Obstetrics and Gynaecology
15 Jul 2020Assigned to Editor
15 Jul 2020Submission Checks Completed
17 Jul 2020Reviewer(s) Assigned
01 Sep 2020Review(s) Completed, Editorial Evaluation Pending